Zynex Medical - Investor Relations

Zynex Reports Increase in Electrotherapy Orders for March

LONE TREE, Colo., April 8, 2016 /PRNewswire/ — Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today March orders for the electrotherapy product line.

Thomas Sandgaard, Founder and CEO of Zynex said: “In March we processed 3,006 patient files, primarily for our NexWave electrotherapy device. This represents about a 7%, month over month, increase from our February 2016 order level for electrotherapy products.

We are still experiencing bottlenecks keeping pace with the increased level of new orders, as well as providing demo units for clinics that our many new sales reps have been servicing for years while they were previously representing Empi. We are working diligently with our lenders to obtain additional funds to support the higher activity level.”

Revenue from the placement of a NexWave electrotherapy unit is normally derived over time from monthly billings for the sale or rental, and from monthly supplies during the treatment period after the initial patient order.

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2015.

Contact:
Zynex, Inc.
(303) 703-4906

Logo – http://photos.prnewswire.com/prnh/20160531/373722LOGO

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/zynex-recognized-in-top-100-public-companies-by-coloradobiz-300286342.html

SOURCE Zynex

https://zynexmed.investorroom.com/2016-04-08-Zynex-Reports-Increase-in-Electrotherapy-Orders-for-March